Celplat 50mg Injection (Cisplatin Injection IP)

Celplat 50mg Injection is a prescription medicine containing Cisplatin. It is supplied in a 50mg injection presentation and belongs to the platinum-containing cytotoxic chemotherapy class. It should be used only under the supervision of a clinician experienced in the relevant disease area.
Advanced testicular cancer: Cisplatin Injection is used as a component of curative multi-agent chemotherapy regimens. Advanced ovarian cancer: Celplat 50mg has an established role in platinum-based treatment, although exact contemporary regimens depend on clinical context.
After entering cells, Cisplatin 50mg Injection undergoes aquation and forms reactive platinum complexes that bind DNA. The resulting intra- and inter-strand DNA cross-links interfere with DNA replication and transcription and can trigger apoptosis. Its antitumour activity is accompanied by characteristic cumulative renal, neurologic and auditory toxicities. The 50mg strength describes the commercial presentation; it does not automatically represent the complete prescribed dose. Dose and duration depend on diagnosis, treatment protocol, organ function, concomitant medicines and treatment tolerance.

Celplat Injection may be prescribed in the following established clinical settings. The exact treatment line, combination regimen and duration depend on the diagnosis, current labeling and specialist assessment.
Advanced testicular cancer: Cisplatin 50mg is used as a component of curative multi-agent chemotherapy regimens.
Advanced ovarian cancer: Cisplatin 50mg Injection has an established role in platinum-based treatment, although exact contemporary regimens depend on clinical context.
Advanced bladder cancer: Celplat 50mg Injection is used in appropriate patients with adequate renal function and performance status.
Cisplatin Injection is also widely incorporated into evidence-based protocols for several other solid tumours; those uses should be described according to the relevant cancer guideline rather than presented as a universal label indication.

After entering cells, cisplatin 50mg Injection undergoes aquation and forms reactive platinum complexes that bind DNA. The resulting intra- and inter-strand DNA cross-links interfere with DNA replication and transcription and can trigger apoptosis. Its antitumour activity is accompanied by characteristic cumulative renal, neurologic and auditory toxicities.

• Clinical evidence in this section relates to the Cisplatin 50mg molecule and relevant treatment regimens; it should not be interpreted as evidence that every pivotal trial specifically studied the Celplat Injection commercial presentation.
  
• Cisplatin Injection-containing combinations produced major improvements in cure rates for germ-cell tumours and became foundational across multiple solid cancers.
  
• Regulatory labeling specifically includes advanced testicular, ovarian and bladder cancers. Modern disease-specific regimens determine the partner drugs, schedule and supportive care.
  
• Evidence should always be tied to the tumour and regimen; a Celplat 50mg vial is simply a presentation used to prepare a protocol-calculated dose.
  
  

The side effects of Cisplatin 50mg Injection vary by indication, dose, treatment duration, concomitant medicines and individual patient factors. Common or clinically relevant effects include:

• Severe nausea and vomiting
  
• Nephrotoxicity
  
• Peripheral neuropathy
  
• Myelosuppression
  
• Ototoxicity including tinnitus/hearing loss
  
• Hypomagnesemia and other electrolyte abnormalities
  
• Fatigue
  
• Loss of appetite

Serious or persistent symptoms should be assessed promptly. The treating team should provide medicine-specific instructions on which symptoms require urgent medical attention.

Celplat 50mg Injection is administered in a healthcare setting. There is no single universal 50mg patient dose.

These are molecule-level examples from regulatory labeling or established product information and are not instructions for self-dosing. The treating specialist determines the actual dose, schedule, dose modifications and supportive medicines.

Celplat 50mg Injection is given according to a scheduled treatment plan. If an appointment or dose is missed or delayed, contact the treating team promptly. Do not attempt to compensate for a missed Cisplatin 50mg dose or alter the treatment cycle without medical advice.

Monitoring is individualized according to the disease and treatment regimen. It may include:

• Serum creatinine, BUN and creatinine clearance
  
• Magnesium, potassium, calcium and other electrolytes
  
• CBC
  
• Hydration status and urine output
  
• Hearing symptoms/audiometry when indicated
  
• Peripheral neuropathy
  
• Nausea/vomiting control
  
• Disease-specific response
  
  

1. DailyMed. Cisplatin for Injection prescribing information, updated June 2026 https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b029f5-0d7e-4e7f-accc-b722aec34c68​
2. Disease-specific oncology treatment guidelines https://www.nccn.org/guidelines/category_1​
3. Current India-specific Celplat package insert should be checked before publication https://pmc.ncbi.nlm.nih.gov/articles/PMC8112326/​
4. Brand-specific Celplat prescribing information / package insert should remain the primary source for manufacturer, exact dosage form, storage, pack configuration and India-specific approved labeling before publication.